Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
Allergan Aesthetics, an AbbVie Company, has launched the new AA Signature program at IMCAS World Congress 2025, introducing an innovative approach to aesthetic treatment planning. The program focuses on delivering personalized, patient-centric solutions through their advanced product portfolio.
Research shows that 8 in 10 patients proceed with treatment following holistic consultation, and clinics using multi-area treatment plans experience a 68% higher retention rate. The program addresses three key patient needs: Lift (structure and skin firmness), Definition (enhanced facial angles), and Skin quality (smoothness and hydration).
The initiative includes advanced training and education modules for healthcare providers (HCPs), supporting them with combination product use and comprehensive educational programs. The program will be gradually introduced worldwide to reflect new trends, products, and indications.
Allergan Aesthetics, una società di AbbVie, ha lanciato il nuovo programma AA Signature al Congresso Mondiale IMCAS 2025, introducendo un approccio innovativo alla pianificazione dei trattamenti estetici. Il programma si concentra sulla fornitura di soluzioni personalizzate e incentrate sul paziente attraverso il loro avanzato portafoglio di prodotti.
Le ricerche dimostrano che 8 pazienti su 10 proseguono con il trattamento dopo una consultazione olistica, e le cliniche che utilizzano piani di trattamento multi-area registrano un 68% di tasso di fidelizzazione in più. Il programma affronta tre esigenze chiave dei pazienti: Sollevamento (struttura e compattezza della pelle), Definizione (angoli facciali migliorati) e Qualità della pelle (lucentezza e idratazione).
L’iniziativa include moduli avanzati di formazione ed educazione per i fornitori di assistenza sanitaria (HCP), supportandoli nell’uso di prodotti in combinazione e in programmi educativi completi. Il programma sarà gradualmente introdotto in tutto il mondo per riflettere le nuove tendenze, i prodotti e le indicazioni.
Allergan Aesthetics, una compañía de AbbVie, ha lanzado el nuevo programa AA Signature en el Congreso Mundial IMCAS 2025, introduciendo un enfoque innovador para la planificación de tratamientos estéticos. El programa se centra en ofrecer soluciones personalizadas y centradas en el paciente a través de su avanzado portafolio de productos.
Investigaciones muestran que 8 de cada 10 pacientes continúan con el tratamiento tras una consulta holística, y las clínicas que utilizan planes de tratamiento multi-área experimentan un 68% de mayor tasa de retención. El programa aborda tres necesidades clave de los pacientes: Elevación (estructura y firmeza de la piel), Definición (ángulos faciales mejorados) y Calidad de la piel (suavidad e hidratación).
La iniciativa incluye módulos avanzados de formación y educación para proveedores de salud (HCP), apoyándolos en el uso de productos combinados y en programas educativos integrales. El programa se introducirá gradualmente en todo el mundo para reflejar nuevas tendencias, productos e indicaciones.
알레르간 에스테틱스, 애브비(AbbVie) 소속,가 IMCAS 세계 총회 2025에서 새로운 AA 시그니처 프로그램을 출시하며 미용 치료 계획에 대한 혁신적인 접근 방식을 소개했습니다. 이 프로그램은 고급 제품 포트폴리오를 통해 개인 맞춤형 및 환자 중심 솔루션을 제공하는 데 중점을 두고 있습니다.
연구에 따르면 10명 중 8명의 환자가 전체적인 상담 후 치료를 진행하며, 다중 영역 치료 계획을 사용하는 클리닉은 68% 더 높은 유지율을 경험합니다. 이 프로그램은 세 가지 주요 환자 요구를 해결합니다: 리프팅(구조 및 피부 탄력), 정의(강화된 얼굴 각도), 그리고 피부 질(부드러움과 수분 공급).
이니셔티브는 건강 관리 제공자(HCP)를 위한 고급 교육 및 학습 모듈을 포함하여, 그들이 조합 제품 사용과 종합적인 교육 프로그램에서 지원 받도록 합니다. 이 프로그램은 새로운 트렌드, 제품, 그리고 지표를 반영하기 위해 전 세계적으로 점진적으로 도입될 것입니다.
Allergan Aesthetics, une société d'AbbVie, a lancé le nouveau programme AA Signature lors du Congrès Mondial IMCAS 2025, introduisant une approche innovante de la planification des traitements esthétiques. Le programme se concentre sur la fourniture de solutions personnalisées et centrées sur le patient grâce à leur portefeuille de produits avancé.
Des recherches montrent que 8 patients sur 10 poursuivent un traitement après une consultation holistique, et les cliniques utilisant des plans de traitement multi-domaines connaissent un taux de fidélisation supérieur de 68%. Le programme aborde trois besoins clés des patients : Lifting (structure et fermeté de la peau), Définition (angles faciaux améliorés) et Qualité de la peau (légèreté et hydratation).
L'initiative comprend des modules de formation et d'éducation avancés pour les prestataires de soins de santé (HCP), les soutenant dans l'utilisation de produits combinés et des programmes éducatifs complets. Le programme sera progressivement introduit mondialement pour refléter les nouvelles tendances, produits et indications.
Allergan Aesthetics, ein Unternehmen von AbbVie, hat das neue AA Signature Programm beim IMCAS Weltkongress 2025 vorgestellt und einen innovativen Ansatz zur Planung ästhetischer Behandlungen eingeführt. Das Programm konzentriert sich darauf, personalisierte, patientenzentrierte Lösungen durch ihr fortschrittliches Produktportfolio anzubieten.
Studien zeigen, dass 8 von 10 Patienten nach einer ganzheitlichen Beratung mit der Behandlung fortfahren, und Kliniken, die Multi-Bereich-Behandlungspläne anwenden, eine 68% höhere Bindungsrate erfahren. Das Programm adressiert drei wesentliche Patientenbedürfnisse: Lifting (Struktur und Hautfestigkeit), Definition (verbesserte Gesichtswinkel) und Hautqualität (Glätte und Feuchtigkeit).
Die Initiative umfasst fortschrittliche Schulungs- und Bildungsmodule für Gesundheitsdienstleister (HCPs), die sie bei der Verwendung von Kombinationsprodukten und umfassenden Bildungsprogrammen unterstützen. Das Programm wird weltweit schrittweise eingeführt, um neue Trends, Produkte und Indikationen zu reflektieren.
- High patient conversion rate of 80% following holistic consultation
- 68% higher patient retention rate for clinics using multi-area treatment plans
- Program expansion planned globally to incorporate new products and trends
- None.
- AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
With 8 in 10 patients proceeding with treatment following holistic consultation, this research3+ highlights the power of combining high-quality products to achieve bespoke signature looks. The AA Signature program provides HCPs with advanced training and education modules that harness the potential of Allergan Aesthetics' facial product portfolio.
Program Highlights:
Launching Internationally at IMCAS World Congress 2025, the AA Signature approach focuses on key patient needs frequently seen in clinical practice. Following the launch, more signature looks and approaches using the product portfolio will be gradually introduced around the world* to reflect new trends, products and indications, and to treat different areas of the face. The new AA Signature program addresses different needs, including:
- Lift: Added lift, structure and skin firmness – Patients long for a lifted and more defined appearance4,5> with 9 in 10 people interested in a holistic plan targeting multiple areas of the face.6#
- Definition: Enhanced facial angles and lower face definition – More than 1 in 3 patients seek an improved chin, jawline or side profile.7~
- Skin quality: Smoother and firmer skin with more hydration –
94% of people want to improve their facial skin quality8= and 1 in 2 people worry about their facial skin texture or tone.9^
Delivering results through multimodal excellence
The AA Signature program stems from compelling research demonstrating the benefits of holistic treatments. Clinics utilizing treatment plans addressing multiple areas of the face see a
As the Allergan Aesthetics portfolio continues to expand, the AA Signature approach supports HCPs with the combination use of products to maximize the treatment options available. The AA Signature program offers HCPs cutting-edge training and tools to meet the demands of an increasingly diverse aesthetic environment, ensuring they are equipped to deliver the best possible natural looking results patient's desire.
"The AA Signature program addresses the rising demand for a holistic treatment approach and leverages our advanced product portfolio, providing HCPs with access to expert opinions, business support, and comprehensive educational programs - including consumer-focused and AMI-led provider training - that align with individual patient aesthetic goals," said Mark Wilson, SVP Head of International Commercial, Allergan Aesthetics.
We advise HCPs to contact their local Allergan Aesthetics representative to find out if the AA Signature program is available in their country.
Notes to Editors
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit. www.allerganaesthetics.com.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Global Media: | Investors: |
Michael Salzillo | Liz Shea |
Adelle Infante | |
Disclaimers
Material developed and funded by Allergan Aesthetics, an AbbVie company.
Copyright 2023 AbbVie. All rights reserved. All trademarks are the property of their respective owners.
Footnotes:
+ According to a survey of 242 US HCPs asked what percentage of the time do their new/naïve patients with whom they've discussed a full facial consultation convert to treatment right away or make a future appointment.
> Qualitative data from an online community platform captured over 5 days with a range of consumer types (naïve considerers, engaged considerers, users) from a range of ages (20–34, 34–49 and 50+) from
# According to an online survey conducted in the US between December 2020 and January 2021 of 300 patients aged 18–75 years who used a neurotoxin and/or dermal filler in the past two years.
~ Online interviews completed by 12,360 'aesthetically aware' 25–64-year-old women and men across 15 countries in the
=
^
% Based on a multicentre, retrospective review of patient retention rates from seven aesthetic practices across five continents, incorporating more than 2,600 patients. Patients who received one or more treatments with HA soft-tissue fillers or neuromodulators were retrospectively divided into 1 of 3 groups according to treatment(s) received over a 12-month period: neuromodulator only, HA only, or dual treatment with neuromodulator and HA. Retention rates in each practice at 1, 3, and 5 years after the incident year were calculated as the proportion of patients in each group who received at least one paid treatment in the 12-month period leading up to each time point. At 5 years, patient retention for dual treatment was
References:
- Chiu A et al. Clin Cosmet Investig Dermatol. 2023;16:1521–32.
- Allergan Aesthetics. Data on File. Consumer Filler. March 2021.
- Allergan Aesthetics. Data on Ule. REF-115016. HCP Facial Injectables ATU: Neurotoxins—Final Report. January 2022.
- Chiu A et al. Clin Cosmet Investig Dermatol. 2023;16:1521–32.
- Allergan Aesthetics. Data on File. The Lower Face Customer & HCP Journey: Qualitative Research Report. May 2024.
- Allergan Aesthetics. Data on File. Consumer Filler. March 2021.
- Allergan Aesthetics. Data on File. Consumer Beauty Insights Survey 2021. August 2021.
- Humphrey S, et al. Dermatol Surg. 2021;47(7):974–81.
- Allergan Aesthetics. Data on File. Allergan 360 Report Skin Quality Data. 2019.
- Humphrey S et al. J Cosmet Dermatol. 2021;20:1495–1498.
View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-launches-new-aa-signature-program-at-imcas-2025-to-redefine-patient-centric-multimodal-treatment-plans-302362490.html
SOURCE AbbVie
FAQ
What is the patient conversion rate for Allergan Aesthetics' AA Signature program?
How much higher is the retention rate for clinics using AA Signature's multi-area treatment approach?
What are the three main treatment focuses of ABBV's AA Signature program?
When and where is Allergan Aesthetics launching the AA Signature program?
